Emerging Therapies for the Treatment of Mantle Cell Lymphoma

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

Branding in the health care industry should prioritize communicating empathy and care through every touchpoint.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of using loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.